To develop OliX’s OLX75016 candidate primarily targeting metabolic-associated steatohepatitis (MASH).

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Olix Pharmaceuticals signed a $630 million licensing deal with Eli Lilly to develop treatments for cardiovascular and ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and ...

Olix Pharmaceuticals Inc. walked the talk in realizing a new $630 million licensing deal with Eli Lilly and Co. for its ...

Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...

OliX Pharmaceuticals, a gene therapy developer, recorded a daily limit up on the 10th after news that it signed a global ...

Eli Lilly And Co (NYSE:LLY) inked two strategic collaborations to expand radiopharmaceuticals and metabolic-associated ...

South Korea-based developer of RNAi therapeutics developer OliX Pharmaceuticals has announced a global licensing agreement with Eli Lilly.

OliX and Eli Lilly announced a global licensing agreement, focusing on the development and commercialization of OliX’s ...